

Figure 2. Associations of the *AFF1* locus with SLE. (A) A chromosomal plot of *P*-values in GWAS for SLE. (B) A regional plot in the *AFF1* locus. Diamond-shaped data points represent $-\log_{10}$ (*P*-values) of the SNPs. Large-sized points indicate the *P*-values of the landmark SNP, rs340630 (green for the combined study and red for the GWAS). Density of red color represents r^2 values with rs340630. Blue line represents recombination rates. Lower part indicates RefSeq genes. Gray dashed horizontal lines represent the threshold of $P = 5.0 \times 10^{-8}$. The plots were drawn using SNAP, version 2.1 [47].
doi:10.1371/journal.pgen.1002455.g002

Medical University, the University of Tokyo, and the BioBank Japan Project [36]. All subjects were of Japanese origin and provided written informed consent. SLE cases met the revised American College of Rheumatology (ACR) criteria for SLE [37]. Control subjects were confirmed to be free of autoimmune disease. Some of the SLE cases were included in our previous studies [38–40]. Details of the subjects are summarized in Table S1 and S2. This research project was approved by the ethical committees of the University of Tokyo, RIKEN, and affiliated medical institutes.

Table 2. Associations among previously reported SLE-related loci.

rsID	Chr	Position (bp)	Cytoband	Gene	Allele[a]	Allele 1 freq.		OR (95%CI)	*P*	eQTL[b]	Identified by the studies in[c]	
					1/2	Case	Control				Caucasians	Asians
rs2205960	1	171,458,098	1q25	*TNFSF4*	T/G	0.23	0.18	1.35 (1.19–1.54)	3.0×10^{-6}		+	
rs3024505	1	205,006,527	1q32	*IL10*	A/G	0.019	0.014	1.34 (0.90–2.00)	0.15		+	
rs13385731	2	33,555,394	2p22	*RASGRP3*	C/T	0.90	0.87	1.37 (1.15–1.64)	6.0×10^{-4}	+		+
rs10168266	2	191,644,049	2q32	*STAT4*	T/C	0.37	0.27	1.59 (1.42–1.78)	2.7×10^{-16}		+	
rs6445975	3	58,345,217	3p14	*PXK*	G/T	0.25	0.23	1.09 (0.96–1.23)	0.18	+	+	
rs10516487	4	102,970,099	4q24	*BANK1*	G/A	0.91	0.89	1.28 (1.07–1.53)	0.0070		+	
rs10036748	5	150,438,339	5q33	*TNIP1*	T/C	0.75	0.72	1.16 (1.03–1.31)	0.014			+
rs9501626	6	32,508,322	6p21	*HLA-DRB1*	A/C	0.20	0.12	1.86 (1.62–2.13)	1.0×10^{-18}		+	
rs548234	6	106,674,727	6q21	*PRDM1*	C/T	0.40	0.34	1.30 (1.16–1.44)	2.3×10^{-6}	+	+	
rs2230926	6	138,237,759	6q23	*TNFAIP3*	G/T	0.11	0.069	1.75 (1.47–2.08)	1.9×10^{-10}	+	+	
rs849142	7	28,152,416	7p15	*JAZF1*	C/T	0.999	0.999	2.72 (0.25–29.8)	0.41		+	
rs4917014	7	50,276,409	7p12	*IKZF1*	T/G	0.58	0.53	1.24 (1.11–1.38)	8.1×10^{-5}			+
rs6964720	7	75,018,280	7q11	*HIP1*	G/A	0.25	0.19	1.43 (1.27–1.62)	1.3×10^{-8}			+
rs4728142	7	128,361,203	7q32	*IRF5*	A/G	0.16	0.11	1.48 (1.28–1.72)	2.4×10^{-7}	+	+	
rs2254546	8	11,381,089	8p23	*BLK*	G/A	0.78	0.72	1.42 (1.25–1.61)	4.1×10^{-8}	+	+	
rs1913517	10	49,789,060	10q11	*WDFY4*	A/G	0.32	0.28	1.20 (1.07–1.35)	0.0013			+
rs4963128	11	579,564	11p15	*KIAA1542*	T/C	0.98	0.97	1.58 (1.03–2.44)	0.038	+	+	
rs2732552	11	35,041,168	11p13	*PDHX, CD44*	T/C	0.75	0.73	1.13 (1.00–1.27)	0.056		+	
rs4639966	11	118,078,729	11q23	Intergenic	T/C	0.32	0.28	1.22 (1.09–1.36)	7.3×10^{-4}			+
rs6590330	11	127,816,269	11q24	*ETS1*	A/G	0.48	0.39	1.44 (1.30–1.60)	1.3×10^{-11}			+
rs1385374	12	127,866,647	12q24	*SLC15A4*	T/C	0.19	0.16	1.21 (1.06–1.38)	0.0057			+
rs7329174	13	40,456,110	13q14	*ELF1*	G/A	0.30	0.25	1.32 (1.18–1.49)	2.2×10^{-6}			+
rs7197475	16	30,550,368	16p11	Intergenic	T/C	0.12	0.10	1.20 (1.02–0.41)	0.031			+
rs11150610	16	31,241,737	16p11	*ITGAM*	C/A	0.20	0.19	1.07 (0.94–1.22)	0.32	+	+	
rs12949531	17	13,674,531	17p12	Intergenic	T/C	0.28	0.27	1.02 (0.91–1.15)	0.73		+	
rs463426	22	20,139,185	22q11	*HIC2,UBE2L3*	T/C	0.52	0.48	1.20 (1.08–1.33)	6.1×10^{-4}		+	

[a]Based on forward strand of NCBI Build 36.3.
[b]Defined using gene expression data measured in lymphoblastoid B cell lines [28].
[c]Based on the previously reported studies for SLE susceptibility loci [3–18].
SLE, systemic lupus erythematosus; OR, odds ratio; eQTL, expression quantitative trait locus; GWAS, genome-wide association study.
doi:10.1371/journal.pgen.1002455.t002

Genotyping and quality control

In GWAS, 946 SLE cases and 3,477 controls were genotyped using Illumina HumanHap610-Quad and Illumina HumanHap550v3 Genotyping BeadChips (Illumina, CA, USA), respectively. After the exclusion of 47 SLE cases and 92 controls with call rates <0.98, SNPs with call rates <0.99 in SLE cases or controls,

Table 3. Results of combined study for Japanese patients with SLE.

rsID	Chr	Position (bp)	Cytoband	Gene	Allele	Stage	No. subjects		Allele 1 freq.		OR (95%CI)	*P*	eQTL[a]
					1/2		Case	Control	Case	Control			
rs340630	4	88,177,419	4q21	*AFF1*	A/G	GWAS	891	3,383	0.56	0.51	1.22 (1.10–1.36)	1.5×10^{-4}	+
						Replication study 1	550	646	0.57	0.49	1.40 (1.19–1.64)	4.6×10^{-5}	
						Replication study 2	820	27,911	0.56	0.53	1.14 (1.03–1.26)	0.0094	
						Combined study	2,261	31,940	0.56	0.52	1.21 (1.14–1.30)	8.3×10^{-9}	

[a]Defined using gene expression data measured in lymphoblastoid B cell lines [28].
doi:10.1371/journal.pgen.1002455.t003



Figure 3. Association of rs340630 with *AFF1* expression. (A) Correlation between rs340630 genotypes and transcript levels of *AFF1* (NM_001166693) in EBV-transfected cell lines ($n = 62$) stimulated with PMA. (B) Allele-specific quantification (ASTQ) of *AFF1* transcripts. Allele specific-probes for rs340638 were used for quantification by qPCR. The ratios of A allele over G allele for the amounts of both cDNAs and DNAs were plotted in log scale for each cell line. (C) *AFF1* expression in various tissues. Transcripts levels of *AFF1* were quantified by qPCR and were normalized by *GAPDH* levels.
doi:10.1371/journal.pgen.1002455.g003

non-autosomal SNPs, and SNPs not shared between SLE cases and controls, were excluded. We excluded 7 closely related SLE cases in a 1st or 2nd degree of kinship based on identity-by-descent estimated using PLINK version 1.06 [41]. We then excluded 1 SLE cases and 1 controls whose ancestries were estimated to be distinct from East-Asian populations using PCA performed along with the genotype data of Phase II HapMap populations (release 24) [29] using EIGENSTRAT version 2.0 [42]. Subsequently, SNPs with minor allele frequencies <0.01 in SLE cases or controls, SNPs with exact *P*-values of Hardy-Weinberg equilibrium test $<1.0\times10^{-6}$ in controls, or SNPs with ambiguous cluster plots were excluded. Finally, 430,797 SNPs for 891 SLE cases and 3,384 controls were obtained. Genotyping of SNPs in replication studies was performed using TaqMan Assay or Illumina HumanHap610-Quad Genotyping BeadChip (Illumina, CA, USA).

Association analysis of the SNPs

Association of SNPs in GWAS and replication studies were tested with Cochran-Armitage's trend test. Combined analysis was performed with Mantel-Haenzel method. Associations of previously reported SLE susceptibility loci [3–18] were evaluated using the results of the GWAS. Genotype imputation was performed for non-genotyped SNPs using MACH version 1.0 [43] with Phase II HapMap East-Asian individuals as references [29], as previously described [44]. All imputed SNPs demonstrated imputation scores, *Rsq*, >0.70.

eQTL study

We analyzed gene expression data previously measured in lymphoblastoid B cell lines from Phase II HapMap East-Asian individuals using Illumina's human whole-genome expression array (WG-6 version 1) (accession number; GSE6536) [28]. Expression data were normalized across the individuals. We used BLAST to map 47,294 Illumina array probes onto human autosomal reference genome sequences (Build 36). We discarded probes mapped with expectation values smaller than 0.01 to multiple loci, or for which there was polymorphic HapMap SNP(s) inside the probe. Then, 19,047 probes with exact matches to a unique locus with 100% identity and with a mean signal intensity greater than background were obtained. Genotype data of HapMap individuals were obtained for SNPs included in the GWAS. Associations of SNP genotypes (coded as 0, 1, and 2) with expression levels of each of the cis-eQTL probes (located within ±300 kbp regions of the SNPs) were evaluated using linear regression assuming additive effects of the genotypes on the expression levels. Considering the significant overlap between eQTL and genetic loci responsible for autoimmune diseases [24], we applied relatively less stringent multiple testing threshold of FDR *Q*-values<0.2 for the definition of eQTL. SNPs that exhibited this threshold with any of the corresponding cis-eQTL probes were denoted as eQTL positive.

Selection of SNPs enrolled in the replication studies

In order to select SNPs for further replication studies, we firstly integrated the results of GWAS and eQTL study. SNPs that satisfied $P<1.0\times10^{-4}$ in GWAS, or the SNPs that satisfied $1.0\times10^{-4}\leq P<1.0\times10^{-3}$ in GWAS and denoted as eQTL positive, were selected. Among these, SNPs most significantly associated in each of the genomic loci and not included in the previously reported SLE susceptibility loci [3–18] were further evaluated.

Then, the results of the concurrently proceeding genome-wide scan for SLE in the Japanese subjects using a pooled DNA approach were referred (Tahira T et al. Presented at the 59th Annual Meeting of the American Society of Human Genetics, October 21, 2009). In the scan, DNA collected from 447 SLE cases and 680 controls of Japanese origin were pooled respectively, and genotyped using GeneChip Human Mapping 500K Array Set (Affymetrix, CA, USA). SNPs were ranked according to the Silhouette scores estimated based on relative allele scores (RAS) between SLE cases and controls, and rank-based *P*-values were assigned [30]. By referring to association signals in multiple neighboring SNPs in the pooled analysis, we selected SNPs for replication study 1. Namely, if the SNP of interest was in LD ($r^2>0.5$) or was located within ±100 kbp of SNPs showing association signals in the pooled analysis (rank-based $P<0.01$), it would be selected. SNPs that satisfied $P<1.0\times10^{-6}$ in the combined study of GWAS and replication study 1 were further evaluated in replication study 2 (Figure 1).

Quantification of *AFF1* expression

EBV-transformed lymphoblastoid cell lines ($n=62$) were established by Pharma SNP Consortium (Tokyo, Japan) using peripheral blood lymphocytes of Japanese healthy individuals. Cells were incubated for 2 h in medium alone (RPMI 1640 medium containing 10% FBS, 1% penicillin, and 1% streptomycin) or with 100 ng/ml PMA. Conditions for cell stimulation were optimized before the experiment as previously described [45]. Cells were then harvested and total RNA was isolated using an RNeasy Mini Kit (Qiagen) with DNase treatment. Total RNA (1 µg) was reverse transcribed using TaqMan Gold RT-PCR reagents with random hexamers (Applied Biosystems). Real-time quantitative PCR was performed in triplicate using an ABI PRISM 7900 and TaqMan gene expression assays (Applied Biosystems). Specific probes (Hs01089428_m1) for transcript of *AFF1* (NM_001166693) were used. Expression of *AFF1* in various tissues was also quantified using Premium Total RNA (Clontech). The data were normalized to *GAPDH* levels. *GUS* levels were also evaluated for internal control, and similar results were obtained. Correlation coefficient, R^2, between rs340630 genotypes and transcript levels of *AFF1* was evaluated.

Allele-specific transcript quantification (ASTQ)

ASTQ of *AFF1* in PSC cells was performed as previously described [46]. DNAs were extracted by using a DNeasy Kit (QIAGEN). RNA extraction and cDNA preparation were performed as described above. For PSC cells ($n=17$) that were heterozygous for both rs340630 (the landmark SNP of GWAS) and rs340638 (located in the 5′-untranslated region of *AFF1* and in absolute LD with rs340630), expression levels of *AFF1* were quantified by qPCR on an ABI Prism 7900 using a custom-made TaqMan MGB-probe set for rs340638. Primer sequences were 5′-CTAACTGTGGCCCGCGTTG-3′ and 5′-CCCGGCGCA-GTTTCTGAG-3′. The probe sequences were 5′-VIC-CGAA-GACCGCCAGCGCCCAAC-TAMRA-3′ and 5′-FAM-CGAA-GACCGCCGGCGCCCAA-TAMRA-3′. Ct values of VIC and FAM were obtained for genomic DNA and cDNA samples after 40 cycles of real-time PCR. We also prepared genomic DNA of samples homozygous for each allele and mixed them at different ratios (2:8, 3:7, 4:6, 5:5, 6:4, 7:3, 8:2) to create a standard curve by plotting Ct values of VIC/FAM against the allelic ratio of VIC/FAM for each mixture. Using the standard curve, we calculated the allelic ratios for each genomic DNA and cDNA samples. We measured each sample in quadruplicate in one assay; tests were independently repeated twice.

Web resources

The URLs for data presented herein are as follows.

NCBI GEO, http://www.ncbi.nlm.nih.gov/geo

BioBank Japan Project, http://biobankjp.org

PLINK software, http://pngu.mgh.harvard.edu/~purcell/plink/index.shtml

International HapMap Project, http://www.hapmap.org

EIGENSTRAT software, http://genepath.med.harvard.edu/~reich/Software.htm

MACH and mach2qtl software, http://www.sph.umich.edu/csg/abecasis/MACH/index.html

SNAP, http://www.broadinstitute.org/mpg/snap/index.php

Supporting Information

Figure S1 Principal component analysis (PCA) plot of the subjects. PCA plot of subjects enrolled in the GWAS for SLE. SLE cases and the controls enrolled in the GWAS are plotted based on

eigenvectors 1 and 2 obtained from the PCA using EIGENSTRAT version 2.0 [42], along with European (CEU), African (YRI), Japanese (JPT), and Chinese (CHB) individuals obtained from the Phase II HapMap database (release 22) [29]. Subjects who were estimated to be outliers in terms of ancestry from East-Asian (JPT+CHB) clusters and excluded from the study are indicated by black arrows.
(TIF)

Figure S2 Quantile-Quantile plot (QQ-plot) of *P*-values in the GWAS for SLE. The horizontal axis indicates the expected $-\log_{10}$ (*P*-values). The vertical axis indicates the observed $-\log_{10}$ (*P*-values). The QQ-plot for the *P*-values of all SNPs that passed the quality control criteria is indicated in blue. The QQ-plot for the *P*-values after the removal of SNPs included in the previously reported SLE susceptibility loci is indicated in black. The gray line represents $y = x$. The SNPs for which the *P*-value was smaller than 1.0×10^{-15} are indicated at the upper limit of the plot.
(TIF)

Table S1 Basal characteristics of cohorts.
(DOC)

Table S2 Frequency of clinical characteristics of SLE in this GWAS.
(DOC)

Table S3 Distributions of eQTL positivity rates of the SNPs.
(DOC)

Table S4 Results of replication study 1 for Japanese patients with SLE.
(DOC)

Table S5 Results of replication studies 1 and 2 for Japanese patients with SLE.
(DOC)

Acknowledgments

We are grateful to Dr. A. Miyatake, the members of the Rotary Club of Osaka-Midosuji District 2660 Rotary International in Japan, the autoimmune disease study group, and the staffs of the BioBank Japan Project for supporting the study and clinical sample collection. We thank the members of the Laboratory for Autoimmune Diseases, CGM, RIKEN, for their assistance.

Author Contributions

Conceived and designed the experiments: Y. Okada, K. Shimane, Y. Kochi, A. Suzuki, M. Kubo, N. Kamatani, R. Yamada, Y. Nakamura, K. Yamamoto. Performed the experiments: Y. Kochi, N. Hosono, M. Kubo, K. Myouzen, T. Horiuchi, T. Tahira, K. Hayashi. Analyzed the data: Y. Okada, A. Takahashi, T. Tsunoda, K. Higasa, R. Yamada. Contributed reagents/materials/analysis tools: T. Horita, T. Atsumi, T. Koike, T. Ishii, A. Okamoto, K. Fujio, M. Hirakata, H. Amano, Y. Takasaki, Y. Kondo, S. Ito, T. Sumida, K. Takada, A. Mimori, K. Saito, Y. Tanaka, M. Kamachi, N. Nishimoto, Y. Kawaguchi, C. Terao, K. Ohmura, T. Mimori, F. Matsuda, O.W. Mohammed, K. Matsuda, K. Shimane, K. Ikari, H. Yamanaka. Wrote the paper: Y. Okada, K. Shimane, Y. Kochi, A. Suzuki, R. Yamada, K. Yamamoto.

References

1. Lipsky PE (2001) Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat Immunol 2: 764–766.
2. Sestak AL, Shaver TS, Moser KL, Neas BR, Harley JB (1999) Familial aggregation of lupus and autoimmunity in an unusual multiplex pedigree. J Rheumatol 26: 1495–1499.
3. Sigurdsson S, Nordmark G, Goring HH, Lindroos K, Wiman AC, et al. (2005) Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. Am J Hum Genet 76: 528–537.
4. Graham RR, Kozyrev SV, Baechler EC, Reddy MV, Plenge RM, et al. (2006) A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nat Genet 38: 550–555.
5. Graham RR, Kyogoku C, Sigurdsson S, Vlasova IA, Davies LR, et al. (2007) Three functional variants of IFN regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus. Proc Natl Acad Sci U S A 104: 6758–6763.
6. Remmers EF, Plenge RM, Lee AT, Graham RR, Hom G, et al. (2007) STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N Engl J Med 357: 977–986.
7. Cunninghame Graham DS, Graham RR, Manku H, Wong AK, Whittaker JC, et al. (2008) Polymorphism at the TNF superfamily gene TNFSF4 confers susceptibility to systemic lupus erythematosus. Nat Genet 40: 83–89.
8. Nath SK, Han S, Kim-Howard X, Kelly JA, Viswanathan P, et al. (2008) A nonsynonymous functional variant in integrin-alpha(M) (encoded by ITGAM) is associated with systemic lupus erythematosus. Nat Genet 40: 152–154.
9. Harley JB, Alarcon-Riquelme ME, Criswell LA, Jacob CO, Kimberly RP, et al. (2008) Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat Genet 40: 204–210.
10. Kozyrev SV, Abelson AK, Wojcik J, Zaghlool A, Linga Reddy MV, et al. (2008) Functional variants in the B-cell gene BANK1 are associated with systemic lupus erythematosus. Nat Genet 40: 211–216.
11. Hom G, Graham RR, Modrek B, Taylor KE, Ortmann W, et al. (2008) Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX. N Engl J Med 358: 900–909.
12. Graham RR, Cotsapas C, Davies L, Hackett R, Lessard CJ, et al. (2008) Genetic variants near TNFAIP3 on 6q23 are associated with systemic lupus erythematosus. Nat Genet 40: 1059–1061.
13. Musone SL, Taylor KE, Lu TT, Nititham J, Ferreira RC, et al. (2008) Multiple polymorphisms in the TNFAIP3 region are independently associated with systemic lupus erythematosus. Nat Genet 40: 1062–1064.
14. Han JW, Zheng HF, Cui Y, Sun LD, Ye DQ, et al. (2009) Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus. Nat Genet 41: 1234–1237.
15. Gateva V, Sandling JK, Hom G, Taylor KE, Chung SA, et al. (2009) A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus. Nat Genet 41: 1228–1233.
16. Yang W, Shen N, Ye DQ, Liu Q, Zhang Y, et al. (2010) Genome-wide association study in Asian populations identifies variants in ETS1 and WDFY4 associated with systemic lupus erythematosus. PLoS Genet 6: e1000841. doi:10.1371/journal.pgen.1000841.
17. Lessard CJ, Adrianto I, Kelly JA, Kaufman KM, Grundahl KM, et al. (2011) Identification of a systemic lupus erythematosus susceptibility locus at 11p13 between PDHX and CD44 in a multiethnic study. Am J Hum Genet 88: 83–91.
18. Yang J, Yang W, Hirankarn N, Ye DQ, Zhang Y, et al. (2011) ELF1 is associated with systemic lupus erythematosus in Asian populations. Hum Mol Genet 20: 601–607.
19. Hopkinson ND, Doherty M, Powell RJ (1994) Clinical features and race-specific incidence/prevalence rates of systemic lupus erythematosus in a geographically complete cohort of patients. Ann Rheum Dis 53: 675–680.
20. Danchenko N, Satia JA, Anthony MS (2006) Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus 15: 308–318.
21. Yang J, Benyamin B, McEvoy BP, Gordon S, Henders AK, et al. (2010) Common SNPs explain a large proportion of the heritability for human height. Nat Genet 42: 565–569.
22. Raychaudhuri S, Plenge RM, Rossin EJ, Ng AC, Purcell SM, et al. (2009) Identifying relationships among genomic disease regions: predicting genes at pathogenic SNP associations and rare deletions. PLoS Genet 5: e1000534. doi:10.1371/journal.pgen.1000534.
23. Cantor RM, Lange K, Sinsheimer JS (2010) Prioritizing GWAS results: A review of statistical methods and recommendations for their application. Am J Hum Genet 86: 6–22.
24. Dubois PC, Trynka G, Franke L, Hunt KA, Romanos J, et al. (2010) Multiple common variants for celiac disease influencing immune gene expression. Nat Genet 42: 295–302.
25. Cookson W, Liang L, Abecasis G, Moffatt M, Lathrop M (2009) Mapping complex disease traits with global gene expression. Nat Rev Genet 10: 184–194.
26. Kochi Y, Okada Y, Suzuki A, Ikari K, Terao C, et al. (2010) A regulatory variant in CCR6 is associated with rheumatoid arthritis susceptibility. Nat Genet 42: 515–519.
27. Yamaguchi-Kabata Y, Nakazono K, Takahashi A, Saito S, Hosono N, et al. (2008) Japanese population structure, based on SNP genotypes from 7003 individuals compared to other ethnic groups: effects on population-based association studies. Am J Hum Genet 83: 445–456.
28. Stranger BE, Nica AC, Forrest MS, Dimas A, Bird CP, et al. (2007) Population genomics of human gene expression. Nat Genet 39: 1217–1224.
29. The International HapMap Consortium (2003) The International HapMap Project. Nature 426: 789–796.

30. Pearson JV, Huentelman MJ, Halperin RF, Tembe WD, Melquist S, et al. (2007) Identification of the genetic basis for complex disorders by use of pooling-based genomewide single-nucleotide-polymorphism association studies. Am J Hum Genet 80: 126–139.
31. Xia ZB, Popovic R, Chen J, Theisler C, Stuart T, et al. (2005) The MLL fusion gene, MLL-AF4, regulates cyclin-dependent kinase inhibitor CDKN1B (p27kip1) expression. Proc Natl Acad Sci U S A 102: 14028–14033.
32. Isnard P, Core N, Naquet P, Djabali M (2000) Altered lymphoid development in mice deficient for the mAF4 proto-oncogene. Blood 96: 705–710.
33. Schadt EE, Molony C, Chudin E, Hao K, Yang X, et al. (2008) Mapping the genetic architecture of gene expression in human liver. PLoS Biol 6: e107. doi:10.1371/journal.pbio.0060107.
34. Ernst J, Kheradpour P, Mikkelsen TS, Shoresh N, Ward LD, et al. (2011) Mapping and analysis of chromatin state dynamics in nine human cell types. Nature 473: 43–49.
35. Stahl EA, Raychaudhuri S, Remmers EF, Xie G, Eyre S, et al. (2010) Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nat Genet 42: 508–514.
36. Nakamura Y (2007) The BioBank Japan Project. Clin Adv Hematol Oncol 5: 696–697.
37. Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40: 1725.
38. Suzuki A, Yamada R, Kochi Y, Sawada T, Okada Y, et al. (2008) Functional SNPs in CD244 increase the risk of rheumatoid arthritis in a Japanese population. Nat Genet 40: 1224–1229.
39. Shimane K, Kochi Y, Horita T, Ikari K, Amano H, et al. (2010) The association of a nonsynonymous single-nucleotide polymorphism in TNFAIP3 with systemic lupus erythematosus and rheumatoid arthritis in the Japanese population. Arthritis Rheum 62: 574–579.
40. Myouzen K, Kochi Y, Shimane K, Fujio K, Okamura T, et al. (2010) Regulatory polymorphisms in EGR2 are associated with susceptibility to systemic lupus erythematosus. Hum Mol Genet 19: 2313–2320.
41. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, et al. (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81: 559–575.
42. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, et al. (2006) Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 38: 904–909.
43. Li Y, Willer C, Sanna S, Abecasis G (2009) Genotype imputation. Annu Rev Genomics Hum Genet 10: 387–406.
44. Okada Y, Takahashi A, Ohmiya H, Kumasaka N, Kamatani Y, et al. (2011) Genome-wide association study for C-reactive protein levels identified pleiotropic associations in the IL6 locus. Hum Mol Genet 20: 1224–1231.
45. Aikawa Y, Yamamoto M, Yamamoto T, Morimoto K, Tanaka K (2002) An anti-rheumatic agent T-614 inhibits NF-kappaB activation in LPS- and TNF-alpha-stimulated THP-1 cells without interfering with IkappaBalpha degradation. Inflamm Res 51: 188–194.
46. Akamatsu S, Takata R, Ashikawa K, Hosono N, Kamatani N, et al. (2010) A functional variant in NKX3.1 associated with prostate cancer susceptibility down-regulates NKX3.1 expression. Hum Mol Genet 19: 4265–4272.
47. Johnson AD, Handsaker RE, Pulit SL, Nizzari MM, O'Donnell CJ, et al. (2008) SNAP: a web-based tool for identification and annotation of proxy SNPs using HapMap. Bioinformatics 24: 2938–2939.

Mod Rheumatol
DOI 10.1007/s10165-012-0785-8

RAPID COMMUNICATION

The crucial roles of IFN-γ in the development of M3 muscarinic acetylcholine receptor induced Sjögren's syndrome-like sialadenitis

Mana Iizuka · Hiroto Tsuboi · Naomi Matsuo · Yuya Kondo · Hiromitsu Asashima · Minoru Matsui · Isao Matsumoto · Takayuki Sumida

Received: 20 July 2012 / Accepted: 10 October 2012
© Japan College of Rheumatology 2012

Keywords Sjögren's syndrome · M3 muscarinic acetylcholine receptor · IFN-γ · Apoptosis · Sialadenitis

Sjögren's syndrome (SS) is a chronic autoimmune disease characterized by infiltration of lymphocytes into lacrimal and salivary glands, and clinically by dry eyes and dry mouth. Auto-antigens recognized by T cells infiltrating the salivary glands of patients with SS have been analyzed, and several candidate auto-antigens such as M3 muscarinic acetylcholine receptor (M3R) have been identified. The presence and specificity of anti-M3R antibodies in patients with SS have been examined [1–3]. We also reported the presence of IFN-γ-producing M3R-reactive $CD4^+$ T cells in 40 % of SS patients with SS [4]. Several studies also detected high levels of IFN-γ in the salivary glands of SS patients, and then enhanced activity of T cells, B cells, and macrophages, resulting in the destruction and dysfunction of tissue glands [5, 6]. In contrast, IL-17-producing T cells were also found in salivary glands from patients with SS [7].

Our previous study showed that M3R-reactive T cells were involved in the pathogenesis of sialadenitis using M3R-induced sialadenitis (MIS) mice, which are thought to be model mice for SS. In MIS mice, $CD3^+$ T cells were essential for the generation of sialadenitis. Moreover, both IFN-γ and IL-17 were produced by M3R-reactive T cells and were detected in salivary glands, whereas neither IFN-γ nor IL-17 was detected in the sera [8]. However, we have no evidence that the cytokines INF-γ and/or IL-17 are important in the development of sialadenitis. In the present study, to address the question of whether IFN-γ is important in the development of sialadenitis, we generated $M3R^{-/-} \times IFN\text{-}\gamma^{-/-}$ mice, immunized with M3R peptides, and transferred their splenic cells to $Rag\text{-}1^{-/-}$ mice.

Histological findings showed that sialadenitis was more severe in $M3R^{-/-} \times IFN\text{-}\gamma^{-/-} \rightarrow Rag1^{-/-}$ than that in $M3R^{+/+} \rightarrow Rag1^{-/-}$ mice, but milder than that in $M3R^{-/-} \rightarrow Rag1^{-/-}$ mice (Fig. 1a). Quantitative analysis using histological scores indicated that mononuclear cell infiltration was significantly increased in $M3R^{-/-} \times IFN\text{-}\gamma^{-/-} \rightarrow Rag1^{-/-}$ mice compared with that in $M3R^{+/+} \rightarrow Rag1^{-/-}$ mice ($P < 0.05$), but significantly decreased compared with that in $M3R^{-/-} \rightarrow Rag1^{-/-}$ mice ($P < 0.05$) (Fig. 1b). These observations support the notion that IFN-γ might play a crucial role in the generation of SS-like sialadenitis. The absence of IFN-γ- and presence of IL-17-producing cells in the salivary glands of $M3R^{-/-} \times IFN\text{-}\gamma^{-/-} \rightarrow Rag1^{-/-}$ mice were verified by immunohistochemical staining (Fig. 1c). IL-17-producing cells in inflammatory lesions were identified in both $M3R^{-/-} \times IFN\text{-}\gamma^{-/-} \rightarrow Rag1^{-/-}$ and $M3R^{-/-} \rightarrow Rag1^{-/-}$ mice. IFN-γ and IL-17 were not detected in sera from $M3R^{-/-} \times IFN\text{-}\gamma^{-/-} \rightarrow Rag1^{-/-}$ mice, nor in $M3R^{-/-} \rightarrow Rag1^{-/-}$ mice (data not shown). In $M3R^{-/-} \rightarrow Rag1^{-/-}$ mice, the expression of IL-17 was also observed in salivary glands, as was IFN-γ expression. As we have no direct evidence in support of a pathogenic role of IL-17 in MIS, further studies using $M3R^{-/-} \times IL\text{-}17^{-/-}$ mice will be necessary to clarify the function of IL-17-producing M3R-reactive T cells.

M. Iizuka · H. Tsuboi · N. Matsuo · Y. Kondo · H. Asashima · I. Matsumoto · T. Sumida (✉)
Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, 1-1-1 Tenodai, Tsukuba, Ibaraki 305-8575, Japan
e-mail: tsumida@md.tsukuba.ac.jp

M. Matsui
Departments of Clinical Research and General Medicine, Tokyo-Nishi Tokushukai Hospital, Tokyo, Japan

Published online: 26 October 2012

Springer



Fig. 1 MIS was reduced in $M3R^{-/-} \times IFN\text{-}\gamma^{-/-} \rightarrow Rag1^{-/-}$ mice. **a** Salivary glands isolated from $Rag1^{-/-}$ mice at day 45 after inoculation of splenocytes from $M3R^{+/+}$, $M3R^{-/-}$, and $IFN\text{-}\gamma^{-/-}$/$M3R^{-/-}$ mice immunized with M3R peptides encoding the extracellular domains of M3R on days 0 and 10. On the day of immunization, 500 ng of pertussis toxin were injected intraperitoneally. Ten days after booster immunization, the spleens were isolated and transferred into $Rag1^{-/-}$ mice. The salivary glands from $M3R^{+/+} \rightarrow Rag1^{-/-}$, $M3R^{-/-} \rightarrow Rag1^{-/-}$, and $M3R^{-/-}xIFN\text{-}\gamma^{-/-} \rightarrow Rag1^{-/-}$ mice were sliced into 4-μm-thick sections, and each section was stained with Mayer's hematoxylin and eosin (H&E). The original magnification was ×100. Representative images of 3–5 mice from each group. **b** The infiltrating cells in salivary glands from $M3R^{+/+} \rightarrow Rag1^{-/-}$, $M3R^{-/-} \rightarrow Rag1^{-/-}$ and $M3R^{-/-} \times IFN\text{-}\gamma^{-/-} \rightarrow Rag1^{-/-}$ mice were estimated by histological score. The mean + SD are shown. $*P < 0.05$ (Student's *t* test). **c** Immunohistochemical analysis of IFN-γ and IL-17 in salivary glands of $M3R^{-/-} \rightarrow Rag1^{-/-}$ and $M3R^{-/-} \times IFN\text{-}\gamma^{-/-} \rightarrow Rag1^{-/-}$ mice. The stained sections were counterstained with H&E, and were observed at 30× the original magnification. Representative images of three mice from each group. **d** Apoptotic cells in salivary glands from $M3R^{+/+} \rightarrow Rag1^{-/-}$, $M3R^{+/+} \rightarrow Rag1^{-/-}$, and $M3R^{-/-} \times IFN\text{-}\gamma^{-/-} \rightarrow Rag1^{-/-}$ mice were measured by TUNEL staining and described as the number of cells in the objective area of 4 mm^2. Data were analyzed in three fields per section. The mean + SD are shown. $*P < 0.05$ (Student's *t* test)

Several studies have shown that IFN-γ is able to stimulate various cells to express Fas, which triggers apoptosis when stimulated by FasL for its ligand [9, 10]. In our study, the number of apoptotic cells in salivary glands in $M3R^{-/-} \times IFN\text{-}\gamma^{-/-} \rightarrow Rag1^{-/-}$ mice was significantly reduced compared to the number of apoptotic cells in salivary glands in $M3R^{-/-} \rightarrow Rag1^{-/-}$ mice ($P < 0.05$), although apoptotic cells were enhanced in $M3R^{-/-} \rightarrow Rag1^{-/-}$ mice in comparison with those in $M3R^{+/+} \rightarrow Rag1^{-/-}$ mice (Fig. 1c). These findings indicate that IFN-γ plays an important role in the apoptosis of epithelial cells and mononuclear cells in salivary glands in MIS mice.

In conclusion, our observations support the notion that IFN-γ-producing M3R-reactive T cells play a crucial role in the generation of SS-like sialadenitis via the induction of apoptosis. Hence, these results suggest the possibility that IFN-γ-targeting therapy could be used to regulate autoimmune sialadenitis in patients with SS.

Acknowledgments This work was supported by Health and Labour Science Research Grants (2012) for research on intractable diseases, The Clinical Study Group for Autoimmune Diseases.

Conflict of interest None.

References

1. Naito Y, Matsumoto I, Wakamatsu E, Goto D, Sugihara T, Matsumura R, et al. Muscarinic acetylcholine receptor autoantibodies in patient with Sjögren's syndrome. Ann Rheum Dis. 2005;64:510–1.
2. Tsuboi H, Matsumoto I, Wakamatsu E, Nakamura Y, Iizuka M, Hayashi T, et al. New epitopes and function of anti-M3

muscarinic acetylcholine receptor antibodies in patients with Sjögren's syndrome. Clin Exp Immunol. 2010;162(1):53–61.
3. Dawson LJ, Stanbury J, Venn N, Hasdimir B, Rogers N, Smith M. Antimuscarinic antibodies in primary Sjögren's syndrome reversibly inhibit the mechanism of fluid secretion by human submandibular salivary acinar cells. Arthritis Rheum. 2006;54: 1165–73.
4. Naito Y, Matsumoto I, Wakamatsu E, Goto D, Ito S, Tsutsumi A, et al. Altered peptide ligand regulate muscarinic acetylcholine receptor reactive T cells of patients with Sjögren's syndrome. Ann Rheum Dis. 2006;65:269–71.
5. Mitsias DI, Tzioufas AG, Veiopoulou C, Zintaras E, Tassios K, Kogopoulou O, et al. The Th1/Th2 cytokine balance changes with the progress of the immunopathological lesion of Sjogren's syndrome. Clin Exp Immunol. 2002;128(3):562–8.
6. Wakamatsu E, Matsumoto I, Yasukochi T, Naito Y, Goto D, Mamura M, et al. Overexpression of phosphorylated STAT-1 alpha in the labial salivary glands of patients with Sjögren's syndrome. Arthritis Rheum. 2006;54(11):3476–84.
7. Sakai A, Sugawara Y, Kuroishi T, Sasano T, Sugawara S. Identification of IL-18 and Th17 cells in salivary glands of patients with Sjögren's syndrome, and amplification of IL-17-mediated secretion of inflammatory cytokines from salivary gland cells by IL-18. J Immunol. 2008;181(4):2898–906.
8. Iizuka M, Wakamatsu E, Tsuboi H, Nakamura Y, Hayashi T, Matsui M, et al. Pathogenic role of immune response to M3 muscarinic acetylcholine receptor in Sjögren's syndrome-like sialoadenitis. J Autoimmun. 2010;35(4):383–9.
9. Xu X, Fu XY, Plate J, Chong A. IFN-γ induces cell growth inhibition by Fas-mediated apoptosis: requirement of STAT1 protein for up-regulation of Fas and FasL expression. Cancer Res. 1998;58(13):2832–7.
10. Bulosan M, Pauley KM, Yo K, Chan E, Katz J, Peck AB, et al. Inflammatory caspases are critical for enhanced cell death in the target tissue of Sjögren's syndrome before disease onset. Immunol Cell Biol. 2009;87(1):81–90.

Mod Rheumatol
DOI 10.1007/s10165-012-0704-z

ORIGINAL ARTICLE

The predictive value of anti-SS-A antibodies titration in pregnant women with fetal congenital heart block

Ai Anami · Kotaro Fukushima · Yoshinari Takasaki · Takayuki Sumida · Masako Waguri · Norio Wake · Atsuko Murashima

Received: 7 March 2012 / Accepted: 13 June 2012
© Japan College of Rheumatology 2012

Abstract
Objective Fetal congenital complete heart block (CHB) is irreversible and is associated with significant mortality and morbidity. Anti-SS-A antibodies in the maternal sera are involved in its pathogenesis; however, the predictive value of the antibody titer and its role in prediction of this complication are controversial. The aim of this study was to determine the predictive value of maternal anti-SS-A antibodies on the development of fetal CHB.
Methods A retrospective chart review was performed for 189 cases of positive anti-SS-A antibodies determined by the double immunodiffusion (DID) method, and included 17 patients that developed fetal CHB. The relationship between the appearance of CHB and the anti-SS-A antibodies titer was examined.
Results An anti-SS-A antibodies titer of 1:32 or higher was identified by analyzing the receiver-operating characteristics (area under curve 0.72) curve. An anti-SS-A antibodies titer of 32 or more times greater than the upper limit by DID was a risk factor for fetal CHB (odds ratio 27.77, 95 % confidence interval (CI) 1.91–21.02, $P < 0.05$) in the multivariate analysis. Among 107 cases of anti-SS-A antibodies titers of 1:32 or higher, 65 patients (60.7 %) were treated with oral steroids. Of these, four patients had CHB (6.2 %). This rate of CHB was significantly lower ($P < 0.01$) than the rate in patients not treated with steroids.
Conclusion An anti-SS-A antibodies titer of 1:32 or higher in the maternal sera by DID was an independent risk factor for fetal CHB. In these patients, either antenatally administered prednisolone or betamethasone, was associated with a lower risk of fetal CHB.

Keywords Connective tissue diseases · Anti-SS-A antibodies · Pregnancy

Electronic supplementary material The online version of this article (doi:10.1007/s10165-012-0704-z) contains supplementary material, which is available to authorized users.

A. Anami · K. Fukushima (✉) · N. Wake
Department of Obstetrics and Gynecology, Kyushu University Hospital, Maidashi 3-1-1, Higashi-ku, Fukuoka 812-8582, Japan
e-mail: kfuku@gynob.med.kyushu-u.ac.jp

Y. Takasaki
Department of Rheumatology, School of Medicine, Juntendo University, Tokyo, Japan

T. Sumida
Doctoral Programs in Clinical Science, Department of Clinical Immunology, Graduate School of Comprehensive Human Science, University of Tsukuba, Ibaraki, Japan

M. Waguri
Department of Maternal Medicine, Osaka Medical Center and Research, Institute for Maternal and Child, Osaka, Japan

A. Murashima
Department of Maternal Medicine, National Center for Child Health and Development, Tokyo, Japan

Introduction

Neonatal lupus erythematosus (NLE) is, in many cases a passively acquired autoimmune syndrome in which pathogenic autoantibodies (anti-SS-A antibodies) are transmitted from a mother to her fetus through the placenta. NLE is frequently associated with the presence of anti-SS-A antibodies in the mother [1].

Among the major clinical manifestations in infants with NLE, complete congenital heart block (CHB) is irreversible and requires the early implantation of a permanent

Published online: 04 July 2012

pacemaker. In contrast, the non-cardiac manifestations are transient, resolving by 6 months of age without specific treatment [2]. CHB carries a significant mortality and morbidity including permanent pacing before adulthood [3]. The prevalence of CHB in children from women previously known to have anti-SS-A antibodies is ~1–2 % [4]. Thus, the prevention of CHB is an important issue in the management for pregnant women who test positive for anti-SS-A antibodies.

Several recent reports address the therapeutic approaches for fetal heart block. Findings of the PR interval and dexamethasone evaluation (PRIDE) study suggest that the PR interval should be measured regularly in fetuses at risk of heart block [5, 6]. Regular assessment of the fetal PR interval, however, may prove to be unduly burdensome for patients and physicians [7].

Transplacental steroid therapy has been proposed as a means of preventing CHB. Betamethasones are administered if the mother is positive for anti-SS-A antibodies, or has a history of a previous child with CHB. The efficacy of this, as well as that of dexamethasone, however, remains controversial [8]. Additionally, there is concern regarding the adverse neurodevelopmental effects of prenatal steroid exposure, thus a careful neurological assessment of fetuses treated with steroids is required [9].

The empiric treatment of all pregnant patients who test positive for anti-SS-A antibodies may subject an excessive number of fetuses to the detrimental effects of steroids. Therefore, a need exists for a means by which to identify the subset of fetuses at high risk of CHB who may benefit from steroids. While the 52 kD SS-A/Ro or 60 kD SS-A/Ro antibodies are clearly associated with CHB, other factors affect susceptibility [8]. For example, a prior history of CHB increases the risk ninefold, to 19 %, in subsequent pregnancies [4, 10]. Therefore, we reviewed the clinical courses of the patients in this study to identify other contributory factors, in addition to the anti-SS-A antibodies titer, that predicted the development of CHB.

Methods

Patients entered in this retrospective study were followed at one of five Japanese tertiary perinatal centers, including Kyushu University Hospital, Juntendo University, the University of Tsukuba, Osaka Medical Center and Research Institute for Maternal and Child, National Center for Child Health and Development, between 1996 and 2009. A total of 214 pregnant women with SS-A antibodies were enrolled in this study, and in 189 cases, anti-SS-A antibodies were titered by DID (double immune—diffusion) using commercially available kits (ENA-2 test, MBL, Nagoya, Japan or SRL, TFB, Tokyo, Japan). The correlation between these kits was verified by the supplier (personal communication).

Serum samples from 189 patients that were positive on an immunofluorescent screening test using HEp-2 cells were analyzed for anti-SS-A antibodies by DID in each laboratory using its current in-house methodology. The protocol numbers were: 21-71, 21-114, 22-610, 364 and 436 for Kyushu University Hospital, Juntendo University, University of Tsukuba, Osaka Medical Center and Research Institute for Maternal and Child, National Center for Child Health and Development, respectively. The study protocol opened for enrollment at each institution following approval by the ethics committee at each site.

The patients were divided into two groups based on whether the fetus developed CHB. A retrospective chart review was then performed to record maternal demographic characteristics, such as maternal age, parity, gestational week at delivery, frequency of premature delivery, deviation from standard birth weight, APGAR score (low APGAR at 5 min <7), antibody titer by DID, signs and symptoms of maternal autoimmune disease, and medications taken before and during the pregnancy. The deviation from the standard birth weight, a widely accepted method for evaluating the fetal growth, was calculated using the following formula: [(Mean weight at corresponding gestational week)-(actual BW)]/(Standard deviation at the corresponding gestational week) [11, 12].

Mean birth weight and the standard deviation at certain gestational ages were calculated using a formula derived from normal values for the Japanese population.

Multiple logistic regression and a receiver-operating characteristics (ROC) curve for levels of anti-SS-A antibodies by DID in the prediction of fetal CHB were calculated using EXCELL Tokei 2010—in Japanese (Shakai Joho Service, Tokyo, Japan). Statistical analysis was performed using the Mann-Whitney test, Chi-square test, and the unpaired t test programmed in GraphPad Prism® (GraphPad Software, Inc., CA). A P value of <0.05 was considered significant.

Results

Clinical profile

Mean age, parity, gestational week at delivery, frequency of premature delivery, birth weight, deviation from the standard birth weight, APGAR score at 5 min, cases with NLE, cases with CHB, in which the elevated anti-SS-A antibodies were demonstrated subsequent to the development of fetal CHB, signs and symptoms of maternal autoimmune disease, diagnosis of maternal autoimmune disease, and medications taken before and during the pregnancy are shown in Table 1.

Table 1 Clinical profiles and comparison of outcomes between cases with or without fetal CHB

	Cases with CHB (n = 17)	Cases without CHB (n = 172)	P values
Age (years)*	30.2 (23.5 to 36.3)	33 (22 to 43.1)	**<0.05**
Gravidity*	0 (0 to 1)	0 (0 to 2)	0.94
Gestational week at delivery*	37 (32 to 39)	38 (29 to 41)	**<0.01**
Premature birth**	5 (29.4 %)	37 (21.5 %)	0.54
Birth weight (g)*	2300 (1172 to 3028)	2584 (948 to 3978)	0.05
Deviation from standard birth weight (SD)*	0.7 (−3.7 to 2.4)	−0.8 (−3.9 to 4.4)	0.90
Apgar score (5 min)*	8 (7–9)	9 (0 to 10)	**<0.01**
Previous child with CHB**	0 (0.0 %)	10 (5.8 %)	0.60
Anti-SS-A titer of 1:32 or higher	15 (88.2 %)	93 (54.1 %)	**<0.01**
Signs and symptoms maternal autoimmune disease**	8 (47.1 %)	131 (76.2 %)	<0.01
Diagnosis of maternal autoimmune disease**	8 (47.0 %)	137*** (79.6 %)	<0.01
Medications taken before and during	4 (23.5 %)	120 (69.8 %)	**<0.01**

Bold values indicate statistically significant

* Mean (range),** number of cases (1 %), + except for cases receiving medication after finding out fetal CHB, *CHB* congenital heart block, *NLE* neonatal lupus syndrome, *** includes seven asymptomatic patients diagnosed by chance, *DID* double immunodiffusion

Data are expressed as either the * median (range) or ** number of cases (%). The p values for the comparison between cases with fetal CHB versus cases without fetal CHB were calculated using either * Mann–Whitney test, ** Chi-square test (GraphPad Prism 5®, GraphPad Software, Inc., CA, USA). P values <0.05 were considered significant

Maternal autoimmune disease diagnoses and clinical details are presented in Table 2.

Predicting values (Fig. 1)

One hundred eighty-nine cases were available for evaluation with a receiver-operating characteristics (ROC) curve of the level of anti-SS-A antibodies (DID) and fetal CHB (morbidity). Based on the ROC curve at a cut-off point of 1:32 for the anti-SS-A antibodies titer, the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) were 87.0, 53.0, 17.1, and 97.4 %, respectively, for predicting cases at high risk for CHB with an area under the curve (AUC) of 0.72 (Fig. 1).

Univariate analysis (Table 1)

A univariate analysis was performed analyzing the relationship between CHB and either maternal age, parity, gestational week at delivery, frequency of premature delivery, APGAR score at 5 min, and an anti-SS-A antibodies titer of 1:32 or higher, classification based on the ROC curve, presence of signs and symptoms of maternal autoimmune disease, diagnosis of maternal autoimmune disease, and medications taken before and during the pregnancy (Table 1).

Maternal age, gestational week at delivery, APGAR score at 5 min, an anti-SS-A antibodies titer of 1:32 or higher, presence of signs and symptoms of maternal autoimmune disease, diagnosis of maternal autoimmune disease, and medications taken before and during the pregnancy showed significant correlations.

Table 2 Clinical diagnosis of outcome between cases with or without fetal CHB

	Cases with CHB (n = 17)	Cases without CHB (n = 172)
Diagnosis of maternal autoimmune disease	8 (47.0 %)	137 (79.6 %)
Sjs	4	46
SLE	1	35
MCTD	0	4
APS	0	1
RA	**1**	**9**
Sjs/SLE	0	18
Sis/MCTD	1	3
Sjs/RA	0	5
Sjs/APS	0	1
SLE/APS	0	5
SLE/RA	1	0
SLE/MCTD	0	1
Sjs/SLE/APS	0	1
Sjs/SLE/RA	0	1
Others	0	7

Bold values indicate statistically significant

CHB congenital heart block, *NLE* neonatal lupus syndrome, *SLE* systemic lupus erythematosus, *Sjs* Sjögren syndrome, *RA* rheumatoid arthritis, *APS* Anti-phospholipid syndrome, *MCTD* mixed collagen tissue disease



Fig. 1 Receiver-operating characteristics curve for the anti-SS-A antibodies titer in the prediction of fetal CHB *AUC* area under the curve, *arrow* denotes 32 times in DID

Multivariate analysis (Table 3)

We then performed a multivariate analysis using the seven variables significant to fetal CHB. As shown in Table 3, right panel, the odds ratio (95 % confidence interval) for maternal age, and an anti-SS-A antibodies titer of 1:32 or higher were 0.78 (0.62–0.98), $P < 0.05$; 27.77 (1.87–413.44), $P < 0.05$, respectively.

Efficacy of steroid therapy in patients with an anti-SS-A antibodies titer of 1:32 or higher (Tables 3, 4)

Use of steroids was not a predictor of CHB in the multivariate analysis. The association of steroid use with CHB was therefore assessed in the subset of patients with an anti-SS-A antibodies titer of 1:32 or higher (Table 3).

Among 107 patients with an anti-SS-A antibodies titer of 1:32 or higher, 65 (60.7 %) were treated with steroids taken orally during pregnancy; of these, four patients developed CHB (6.2 %). This percentage was significantly lower ($P < 0.01$) than that of the patients not treated with steroids. Among the patients treated with steroids, no patients (0 of 27) treated with prednisolone (dose: median 7.2 range 2.5–12.5 mg) and four of 38 patients treated with betamethasone (initiated at a dose of 2 mg/day at the gestational age of 12–20 weeks, with tapering after 2 weeks) developed CHB.

Fourteen of 41 patients had received prednisolone prior to receiving betamethasone, with the remaining 27 receiving betamethasone only.

Discussion

In this study we investigated risk factors for the development of CHB in anti-SS-A antibodies positive pregnant women. Our main finding was to establish anti-SS-A antibodies titer of 1:32 as the cut-off value based on analysis of a ROC curve. A multivariate analysis showed that an anti-SS-A antibodies titer of 1:32 or higher by DID was an independent risk factor for fetal CHB.

Franco et al. first described the relationship between maternal anti-SS-A antibodies and components of NLE, particularly CHB. Subsequently, several studies have investigated various antibodies including 52 kD SS-A/Ro or 60 kD SS-A/Ro, which do play significant roles. Little, however, is known regarding the relationship between the development of CHB and the anti-SS-A antibodies titer, and whether this relationship is causal.

The method used to titer the antibodies must be considered when assessing results. ELISA is commonly used given that it is simple to perform and automatable. False positive results, however, are common. The present study utilized DID. This method is the standard method for detecting anti-U1RNP, anti-Sm, anti-SS-A, anti-SS-B, anti-Scl-70, anti-Jo-1 antibodies, and is more reliable than the ELISA method [13].

Recently, in a study of 186 fetuses, Jaeggi et al. [8] identified fetal exposure to anti-SS-A levels ≧50 U/ml as significantly increasing the risk of CHB (5 vs. 0 % for <50 U/ml, odds ratio 7.8; range 0.4–159). This study employed enzyme-linked immunosorbent assay (ELISA) measurements. The ELISA assays utilized in the present and prior study were manufactured by different companies, which may explain the discrepancy in the results. Another recent study describes a standardized method for measuring both of the 52 and 60 kD SS-A antibodies, which is more sensitive and accurate than the conventional ELISA kits and the DID method [14, 15]. Thus, it is possible that further investigation using this new assay may confirm the predictive level of anti-SS-A antibodies by ELISA for CHB.

Another finding in this study was that antepartum steroid treatment with either prednisolone or betamethasone, may reduce the risk of fetal CHB in women with an anti-SS-A antibodies titer of 1:32 or higher. Use of either steroid significantly suppressed CHB in comparison to no treatment irrespective of which steroid was selected. Since orally administered prednisolone is inactivated by placental 11 beta HSD type 2 before reaching fetal heart [16], the effect of prednisolone is to diminish a generalized inflammatory insult and to eliminate the candidate maternal autoantibodies. Therefore, it is likely that the mechanism by which steroids affect CHB is maternal rather than fetal [17].

Table 3 Multivariate analysis for fetal CHB

	Odds ratio	95 % confidence interval	*P* value
Maternal age	0.78	0.62–0.98	**<0.05**
Gestational week at delivery	0.72	0.50–1.04	0.08
Apgar score (5 min)	0.83	0.48–1.42	0.49
Anti-SSA antibody titer 32 times or more	27.77	1.87–413.44	**<0.05**
Signs and symptoms of maternal autoimmune disease	0.86	0.13–5.62	0.88
Diagnosis of maternal autoimmune disease	0.27	0.05–1.48	0.13
Medications taken before and during pregnancy	0.2	0.04–1.06	0.06

Bold values indicate statistically significant

Multivariate analysis of seven predictors of fetal CHB was performed using EXCEL Tokei 2010—in Japanese (Shakai Joho Service, Tokyo, Japan). *P* values <0.05 were considered significant

DID double immunodiffusion

Table 4 Efficacy of steroid therapy in patients with an anti-SS-A titer 1:32 or higher

Steroid treatment	CHB		*P* value	
	Positive	Negative		
No steroids	12	30	<0.01	
Steroids, overall	4	62		
Prednisolone	0	25	<0.01*	0.082**
Bethamethazone	4	37	<0.05*	

* Comparison with patient without steroids

** Comparison between patients with prednisolone and betametazone

Autoimmune associated CHB occurs by a two-stage process. In the first step, maternal autoantibodies bind fetal cardiomyocytes, dysregulate calcium homeostasis, and induce apoptosis in affected cells. This step may clinically correspond to a first-degree heart block, and be reversible. As inflammation progresses, as may be the case in genetically susceptible fetuses, progressive tissue damage will lead to fibrosis, calcification of the AV-node and subsequent CHB [18]. It is plausible that the prevention of CHB is likely due, in part, to anti-inflammatory effects in the fetus. It is likely that suppression of the maternal autoimmune component also plays a role.

Patients with SLE or Sjögren Syndrome exhibit asymptomatic inflammation and fluctuations in the levels of numerous inflammatory cytokines [19]. NF-kappa B promotes a chronic inflammatory response through regulating the expression of genes involved in immuno-inflammatory responses, cell cycle progression, inhibition of apoptosis, and cell adhesion [20]. These inflammatory processes may represent the target of prophylactic prednisolone in SLE mothers. Although the mothers with CHB fetuses were similar to the mothers without affected fetuses in terms of significant obstetrical history including a prior history of CHB in a fetus, it was not possible in the present study design to control for factors related to disease severity. Therefore, it is not possible from the present study to ascertain whether maternal disease modification by steroid treatment was directly related to a decreased risk of fetal heart block.

In our retrospective study, betamethasone was given to 41 patients with individual informed-choice base. Each patient was counseled with the understanding that not only has its efficacy in the prevention of fetal CHB not been established, but there are also possible adverse effects for the mother, including mood disorder, insomnia, and increased appetite, adverse obstetric events such as spontaneous abortion, stillbirth, neonatal adrenal insufficiency and long-term brain development. The protocol was not unified, but basically followed antecedent case reports [21, 22]. In brief, betamethasone was given from around 12 to 26 weeks of gestation, initiated at a dose of 2 mg/day, tapered every 2–4 weeks.

Transplacental steroid treatment carries potential risks. The major concerns with chronic steroid use are negative effects on neurological development, growth retardation, and oligohydramnios as well as hypertension, diabetes, infection, and osteonecrosis and osteoporosis in the mother. Fluorinated steroids have, in both human neonates and animal models, been shown to affect intrauterine growth and the central nervous system development with either single or repeated doses [18, 23]. It is unclear, however, whether the results of these studies are directly applicable to the fetus with CHB. Hutter et al. suggest that the risks of high-dose transplacental steroid treatment are in part avoidable by lowering the dexamethasone dosage [24]. As prednisolone was shown to have an equivalent effect in our study population, it is the preferable formulation as its adverse effects are generally considered acceptable even in early pregnancy [25]. A large, prospective study is necessary to ascertain the effectiveness and safety of prednisolone to prevent fetal CHB in patients with anti-SS-A antibodies titer of 1:32 or higher.

In this study, we found that an anti-SS-A antibodies titer of 1:32 or higher by DID was an independent risk factor for fetal CHB. In these patients, either prednisolone or betamethasone, during pregnancy might reduce fetal CHB. These findings may provide a new clinical strategy to prevent fetal CHB in combination with PR measurements and conventional approaches.

Acknowledgments We thank Ms. Takagai and Mr. Kamakura for their technical assistance. This work was supported in part by a grant-in-aid from the Japan Ministry of Health and Labour (H22-Jisedai-Ippan-007), the Japan Ministry of Education (23591596) and "FUKUOKA" OBGYN Researcher's Charity Foundation Fund.

Conflict of interest None.

References

1. Salomonsson S, Strandberg L. Autoantibodies associated with congenital heart block. Scand Immunol. 2010;72:185–8.
2. Copel J, Buyon J, Kleinman C. Successful in utero therapy of fetal heart block. Am J Obstet Gynecol. 1995;173:1384–90.
3. Buyon J, Waltuck J, Kleinman C, Copel J. In utero identification and therapy of congenital heart block. Lupus. 1995;4:116–21.
4. Buyon J, Hiebert R, Copel J, Craft J, Friedman D, Katholi M, et al. Autoimmune-associated congenital heart block: demographics, mortality, morbidity and recurrence rates obtained from a national neonatal lupus registry. J Am Coll Cardiol. 1998;31:1658–66.
5. Brucato A, Frassi M, Franceschini F, Cimaz R, Faden D, Pisoni MP, et al. Risk of congenital complete heart block in newborns of mothers with anti-Ro/SS-A antibodies detected by counterimmunoelectrophoresis: a prospective study of 100 women. Arthr Rheum. 2001;44:1832–5.
6. Friedman D, Kim M, Copel J, Davis C, Phoon C, Glickstein J, et al. PRIDE investigators. Utility of cardiac monitoring in fetuses at risk for congenital heart block: the PR interval and dexamethasone evaluation (PRIDE) prospective study. Circulation. 2008;29:485–93.
7. Jaeggi E, Silverman E, Laskin C, Kingdom J, Golding F, Weber R. Prolongation of the atrioventricular conduction in fetuses exposed to maternal anti-Ro/SS-A and anti-La/SSB antibodies did not predict progressive heart block. A prospective observational study on the effects of maternal antibodies on 165 fetuses. J Am Coll Cardiol. 2011;57:1487–92.
8. Jaeggi E, Laskin C, Hamilton R, Kingdom J, Silverman E. The importance of the level of maternal anti-Ro/SSA antibodies as a prognostic marker of the development of cardiac neonatal lupus erythematosus a prospective study of 186 antibody-exposed fetuses and infants. J Am Coll Cardiol. 2010;55:2778–84.
9. Brucato A, Astori M, Cimaz R, Villa P, Li Destri M, Chimini L, et al. Normal neuropsychological development in children with congenital complete heart block who may or may not be exposed to high-dose dexamethasone in utero. Ann Rheum Dis. 2006;65:1422–6.
10. Solomon D, Rupel A, Buyon J. Birth order, gender and recurrence rate in autoantibody-associated congenital heart block: implications for pathogenesis and family counseling. Lupus. 2003;12:646–7.
11. Shinozuka N. Fetal biometry and fetal weight estimation: JSUM standardization. Ultrasound Rev Obset Gynecol. 2002;2:156–61.
12. Shinozuka N, Akamatsu N, Sato S, Kanzaki T, Takeuchi H, Natori M, et al. Ellipse tracing fetal growth assessment using abdominal circumference JSUM standardization committee for fetal measurements. J Med Ultrasound. 2000;8:87–94.
13. Jaeggi E, Silverman E, Yoo S, Kingdom J. Is immune-mediated complete fetal atrioventricular block reversible by transplacental dexamethasone therapy? Ultrasound Obstet Gynecol. 2004;23:602–5.
14. Murakami A, Kojima K, Ohya K, Imamura K, Takasaki Y. A new conformational epitope generated by the binding of recombinant 70-kd protein and U1 RNA to anti-U1 RNP autoantibodies in sera from patients with mixed connective tissue disease. Arthr Rheum. 2002;46:3273–82.
15. Tan E, Smolen J, McDougal J, Butcher B, Conn D, Dawkins R, et al. A critical evaluation of enzyme immunoassays for detection of antinuclear autoantibodies of defined specificities. Arthr Rheum. 1999;42:455–64.
16. Wahren-Herlenius M. Specificity and effector mechanisms of autoantibodies in congenital heart block. Curr Opin Immunol. 2006;18:690–6.
17. Saleeb S, Copel J, Friedman D, Buyon JP. Comparison of treatment with fluorinated glucocorticoids to the natural history of autoantibody-associated congenital heart block: retrospective review of the research registry for neonatal lupus. Arthr Rheum. 1999;42:2335–45.
18. Newnham J, Moss T. Antenatal glucocorticoids and growth: single versus multiple doses in animal and human studies. Semin Neonatol. 2001;6:285–92.
19. Ishida H, Muchamuel T, Sakaguchi S, Andrade S, Menon S, Howard M. Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice. J Exp Med. 1994;179:305–10.
20. Okamoto T. NF-kappaB and rheumatic diseases. Endocr Metab Immune Disord Drug Targets. 2006;6:359–72.
21. Buyon J, Clancy R, Friedman D. Cardiac manifestations of neonatal lupus erythematosus: guidelines to management, integrating clues from the bench and bedside. Nat Clin Pract Rheumatol. 2009;5:139–48.
22. Friedman D, Kim M, Copel J, Llanos C, Davis C, Buyon J. Prospective evaluation of fetuses with autoimmune-associated congenital heart block followed in the PR Interval and dexamethasone evaluation (PRIDE) study. Am J Cardiol. 2009;103:1102–6.
23. Thomas T, Stefan L, Rosemarie M, Marvin M, Harry R. Detection of anti-Ro (SS-A) antibodies by gel double diffusion and a 'sandwich' ELISA in systemic and subacute cutaneous lupus erythematosus and Sjögren's syndrome. J Autoimmun. 1991;4:87–96.
24. Hutter D. The benefits of transplacental treatment of isolated congenital complete heart block associated with maternal anti-Ro/SS-A antibodies: a review. Scand J Immunol. 2010;72:235–41.
25. Cederqvist L. Fetal immuno-globulin synthesis following maternal immune-suppression. Am J Obstet Gynecol. 1977;129: 687–90.

Fetal Heart Rate Predictors of Long QT Syndrome

Jason L. Mitchell, MD; Bettina F. Cuneo, MD; Susan P. Etheridge, MD; Hitoshi Horigome, MD; Hsin-Yi Weng, MPH; D. Woodrow Benson, MD, PhD

***Background*—**Fetal long QT syndrome (LQTS) is associated with complex arrhythmias including torsades de pointes and 2° atrioventricular block. Sinus bradycardia has also been associated with fetal LQTS, but little is known of this rhythm manifestation. Our purpose was to characterize the fetal heart rate (FHR)/gestational age (GA) profile of fetal LQTS.

***Methods and Results*—**We ascertained fetal LQTS subjects by family history (Group 1) or fetal arrhythmia referral (Group 2). We compared FHR in LQTS subjects versus normal fetuses. To identify FHR predictors of LQTS, we calculated a bradycardia index as % of LQTS FHR recordings either ≤110 beats per minute (obstetric standard) or ≤3rd percentile for GA. Among 42 LQTS subjects, 26 were in Group 1 and 16 in Group 2. There were 536 normal fetuses. The bradycardia index was only 15% for FHR ≤110 beats per minute, but 66% for FHR ≤3rd percentile for GA. Ten fetuses with complex arrhythmias also had severe and sustained sinus bradycardia throughout gestation. Identifying a fetal proband in Group 2 resulted in LQTS diagnosis in 9 unsuspected members of 6 families.

***Conclusions*—**FHR varies by GA in both normal and LQTS fetuses. Postnatal evaluation of neonates with FHR ≤3rd percentile for GA may improve ascertainment of LQTS in fetuses, neonates, and undiagnosed family members. **(*Circulation*. 2012;126: 2688-2695.)**

Key Words: arrhythmias, cardiac ■ fetus ■ long-QT syndrome

Long QT syndrome (LQTS) is reported to have an incidence of 1 in 2500 individuals. Although QT interval prolongation may be an incidental finding, LQTS typically presents in adolescence or young adult life with syncope, sudden death, or cardiac arrest.[1,2] Less frequently, LQTS presents in the perinatal (fetal/neonatal) period; in this setting morbidity and mortality are high, and torsades de pointes (TdP) and 2° atrioventricular (AV) block are signature rhythms.[3–6] Sinus bradycardia is also a manifestation of fetal LQTS and is reported to be more common than TdP and 2° AV block. For example, as many as 44% to 66% of fetuses diagnosed with LQTS presented with sinus bradycardia at 26 to 40 weeks of gestation.[3,6–8] In most reports, a fetal heart rate (FHR) ≤110 beats per minute (bpm) at any gestational age (GA) raised suspicion of LQTS. Indeed, FHR of ≤110 bpm at any GA is the obstetric definition of sinus bradycardia.[9] However, little is known of the sensitivity of this finding and how it relates to the subsequent diagnosis of LQTS.

Clinical Perspective on p 2695

It is well known that FHR in the normal fetus decreases during gestation from about 175 bpm at 10 weeks to 138 bpm at 40 weeks. This phenomenon is believed to be attributable to the increasing dominance of the parasympathetic nervous system on heart rate control as gestation progresses.[10,11] Despite the association between fetal bradycardia and LQTS, the FHR/GA profile, or the range of FHRs of subjects with LQTS, has not been defined. We wondered whether there might be a pathological FHR in the setting of 1:1 AV conduction that was below normal for GA but >110 bpm that might be a sensitive marker for fetal LQTS. We hypothesized that the FHR/GA profile of LQTS individuals would be different than that of normal individuals and there might be GA-specific or genotype-specific FHR predictors of LQTS.

The purposes of this study were first to define the FHR/GA and rhythm profile of individuals with LQTS mutations and compare this profile with that of a normal control group. Second, we hoped to develop FHR criteria that would improve the recognition of LQTS in the perinatal period.

Methods

This was a study of fetal cardiac rhythm in pediatric subjects with a clinical and genetic diagnosis of LQTS. Participants were

Received May 25, 2012; accepted October 12, 2012.

From the Heart Institute for Children, Oak Lawn, IL (J.L.M., B.F.C.); Primary Children's Medical Center, The University of Utah, Salt Lake City (S.P.E., H.-Y.W.); the Department of Pediatrics, University of Tskuba, Tskuba, Ibaraki, Japan (H.H.); and Cincinnati Children's Hospital Medical Center, The University of Cincinnati Medical School, Cincinnati, OH (D.W.B.).

The online-only Data Supplement is available with this article at http://circ.ahajournals.org/lookup/suppl/doi:10.1161/CIRCULATIONAHA.112.114132/-/DC1.

Correspondence to Bettina Cuneo, MD, the Heart Institute for Children, Hope Children's Hospital, 4440 W 95th Street, Oak Lawn, IL 60453. E-mail bettina.cuneo@advocatehealth.com

© 2012 American Heart Association, Inc.

***Circulation* is available at http://circ.ahajournals.org** **DOI: 10.1161/CIRCULATIONAHA.112.114132**

Downloaded from http://circ.ahajournals.org/ by University of Tsukuba on February 21, 2013

recruited at 3 medical centers (Advocate Hope and Lutheran General Children's Hospitals, Chicago IL; University of Tsukuba, Tsukuba, Ibaraki, Japan; and University of Utah and Primary Children's Medical Center, Salt Lake City, UT). Fetal heart rate in LQTS subjects across GA were compared with FHR from a normal control group across similar GA. Approval from the institutional review boards of each participating center was obtained.

Study Groups

Recruitment of LQTS Subjects

To avoid possible ascertainment bias, we divided LQTS subjects into 2 groups. Subjects in Group 1 had a family history of genetically confirmed LQTS and were under increased surveillance because of a risk of LQTS recurrence. Group 2 consisted of fetuses referred for evaluation of cardiac arrhythmia; in some cases Group 1 subjects were siblings of individuals in Group 2.

Recruitment of Normal Subjects

Normal subjects were recruited from Advocate Christ Medical Center and Hope Children's Hospital. Inclusion criteria were a normal obstetric ultrasound or a normal fetal echocardiogram. Indications for obstetric ultrasound of the normal subjects at 7 to 15 weeks were viability and nuchal translucency screening; indications for echocardiography of the normal subjects at 16 to 40 weeks were maternal diabetes mellitus, advanced maternal age, medication exposure or suspicion of fetal disease (eg, family history of a congenital heart defect). Exclusion criteria for normal subjects at 7 to 40 weeks GA included abnormal nuchal translucency measurement, fetal cardiac arrhythmia or history of arrhythmia, congenital heart defect, or clinically significant noncardiac malformation (eg, spina bifida), or known chromosome abnormality. The FHR of 12 infants evaluated for a maternal or paternal history of LQTS but with negative genetic testing were included in the normal subjects. No subject in the normal Group was related to any subject in LQTS Groups 1 or 2.

Fetal Heart Rate Measurements

LQTS Subjects

FHR of the LQTS subjects were obtained from obstetric records throughout the mother's pregnancy. They were derived from M-mode measurements of ventricular or atrial contractions from 5 consecutive cardiac cycles when the fetus was still, or by Doppler auscultation of the FHR routinely performed at monthly or twice monthly visits to the obstetric care provider. For fetuses with AV block, FHR was determined either during intermittent sinus rhythm or by measuring the atrial rate. Rhythms of LQTS subjects were classified as either sinus or complex, specifically TdP or 2° AV block.

Normal Subjects

Method for determination of FHR in normal fetuses was GA-dependent. FHR at 7 to 15 weeks of gestation were measured from atrial or ventricular M-mode waveforms of 5 consecutive cardiac cycles obtained during routine obstetric ultrasounds. FHR at 16 to 40 weeks of gestation were measured from the aortic or pulmonary valve Doppler waveforms of 5 consecutive cardiac cycles obtained during fetal quiescence. Data were obtained from 10 fetuses for each week of gestation from 7 to 40 weeks.

LQTS Diagnosis

The diagnosis of LQTS was based on findings of a positive genetic test for LQTS. All genetic testing was performed in commercial genetic testing laboratories. Samples were tested for either 12 (GeneDx, Gaithersburg, MD) or 13 (Familion, Transgenomic Inc., New Haven, CT) LQTS gene subtypes. Only genetic variants reported to be deleterious were considered to be mutations; variants reported to be of uncertain significance were not considered pathological. Mutations were classified as LQTS gene type, compound (>1 deleterious mutation), uncharacterized (no mutation in a known LQT gene), or untested. The presence of a signature LQTS rhythm, TdP or 2° AV block, in the fetal or neonatal period was considered confirmatory of the LQTS diagnosis, even if genetic testing revealed no mutation in a known LQTS gene.

The QT interval on a postnatal 12 lead ECG was corrected (QTc) by both Bazett and Frederica formulas and reported for LQTS subjects. Subjects in Group 1 had an ECG at the time of their initial evaluation during infancy or childhood, whereas those in Group 2 had an ECG during the first 24 hours of life.

Fetal Heart Rate Analysis

We determined the 3rd, 50th, and 97th percentiles for FHR/GA of the normal subjects by logarithmic regression analysis. For the purposes of this study, we defined bradycardia in 2 different ways: either independent of GA (FHR ≤110 bpm, the obstetric definition of bradycardia) or dependent on GA (FHR ≤3rd percentile for GA).

Statistical Analysis

The FHR (mean±SE) was calculated for normal subjects and LQTS subjects. To maximize statistical power, we grouped the FHR data into 3 categorical GA groups, (1) <21 weeks, (2) 21 to 30 weeks, and (3) 31 to 40 weeks, and compared normal and LQTS FHR in the 3 GA groups. A mixed effect model was performed taking the dependency of patients within the same family into account. To eliminate maternal β-adrenergic blockade therapy as a confounding variable for observed FHR differences between normal and LQTS subjects, we compared FHR of treated and untreated mothers with LQTS by Mann–Whitney nonparametric testing. A 2-tailed P level of <0.05 was considered statistically significant. All analyses were done using SAS 9.2 (SAS Inc., Cary, NC).

Bradycardia Index of LQTS Subjects

Once we derived the 3rd, 50th, and 97th percentiles for the normal subjects at each GA, we calculated a bradycardia index for each LQTS fetus using both definitions of bradycardia. In other words, the bradycardia index was the ratio of FHR measures that were either ≤110 bpm or ≤3rd percentile for GA compared with the total number of FHR measures for that fetus. Because the number of subjects in each genotype group was small, we did not seek to define a genotype-specific effect on FHR or bradycardia index within categorical age groups or between Groups 1 and 2.

Results

LQTS Subjects

The descriptions of the LQTS cohorts in Group 1 (referred with a family history of LQTS; n=26) and Group 2 (referred for arrhythmia evaluation; n=16) are summarized in Table 1. Among the 42 subjects, a diagnosis of LQTS was made during fetal or neonatal life in 32 subjects; in 10 subjects in Group 1, the diagnosis was made later during infancy or childhood. The QTc intervals corrected by Bazett formula ranged from 450 to 700 (mean 582) ms and corrected by Frederica formula ranged from 394 to 660 (mean 471) ms. Bazett correction resulted in a prolonged QTc (≥ 450 ms) in 95% of genetically proven LQTS subjects, whereas use of Friderica correction identifies only 59% of genetically proven LQTS subjects as having a prolonged QTc. The corrected QT intervals by both formulae are shown in the Table I in the online-only Data Supplement. Several members of Group 1 were in previously reported families.[12–14] Siblings of 4 families were included in Group 1: subjects #10, #11, and #12;

Downloaded from http://circ.ahajournals.org/ at University of Tsukuba on February 21, 2013

Table 1. Study Cohort

ID	GA Arrhythmia Detected (wks)	Age Enrolled	GA Delivery (wks)	LQTS Mutation
Group 1: Referral for Family History of LQTS				
*1(12)	...	F/N	38	*KCNQ1* A341V (13)
2	...	F/N	38	Not tested
3	...	F/N	38	Not tested
4	...	F/N	39	*KCNQ1* R594Q (14)
5	...	3 y	41	*KCNQ1* R259C (15)
6	...	2 y	38	*KCNQ1* G314D (16)
*7	...	5 y	39	*KCNQ1* IVS2+5G>A (splice)(17)
*8	...	2 y	37	*KCNQ1* IVS2+5G>A (splice)(17)
9	...	F/N	39	*KCNQ1* A226V (18)
*10(19)	...	F/N	41	*KCNQ1* W305X (19)
*11	...	F/N	37	*KCNQ1* W305X (19)
*12	...	F/N	37	*KCNQ1* W305X (19)
*13	...	F/N	35	*KCNQ1* R190W (20)
*14	...	F/N	31	*KCNQ1* R591H+*KCNE1* S28L (21)
*15	...	3 y	30	*KCNQ1* R591H (21)
*16	...	F/N	40	*KCNH2* A715A (splice) (17)
†17(22)	...	6 y	40	*KCNQ1* G168R (23)
†18	...	F/N	39	*KCNQ1* G168R (23)
19(14)	...	8 y	40	*KCNE1* D76N (14)
20	...	6 y	41	*KCNE1* D76N (14)
21(13)	...	F/N	40	*KCNQ1* V254M (13)
*22	...	F/N	37	*KCNQ1* V254M (13)
23(24)	...	19 mo	39	*KCNQ1* R518X (25)
24(26)	...	5 y	40	*KCNH2* T1945+6C (26)
25(13)	...	F/N	37	*KCNQ1* A341E (13)
26	...	F/N	39	*SCN5A* T1304M (27)
Group 2: Referral for Fetal Arrhythmia				
27(28)	28	F/N	33	*KCNH2* G628S (29)
28(30)	21	F/N	35	*SCN5A* R1623Q (31)
29	35	F/N	38	Uncharacterized
30	27	F/N	38	Uncharacterized
31	25	F/N	37	*KCNQ1* V110fs+132X‡
32	23	F/N	37	*KCNQ1* R259C (15)
33	22	F/N	38	*KCNQ1* G314D (16)
34	29	F/N	39	*KCNH2* W1001X (32)
35	32	F/N	39	*KCNQ1* R539W (33)
36	31	F/N	35	*SCN5A* R1623Q (29)
37	32	F/N	37	*KCNQ1* A226V (18)
38	30	F/N	40	Not tested
39	32	F/N	38	Uncharacterized
40(34)	19	F/N	IUFD	*SCN5A* L409P (34)‡
41	28	F/N	31	*SCN5A* R1623Q (31)
42	28	F/N	31	*SCN5A* R1623Q (31)

Numbers in parenthesis after subject number are references in which subject was previously described; numbers in parenthesis after mutations are references for first description of mutation. LQTS indicates long QT syndrome; No., number; GA, gestational age; FHR, fetal heart rate; wks, weeks; F/N, fetus/neonate; and IUFD, intrauterine fetal demise.

*Mother with LQTS was on beta blocker treatment during entire pregnancy.

†Mother on β-blocker therapy only during 3rd trimester.

‡Novel mutation.

Downloaded from http://circ.ahajournals.org/ at University of Tsukuba on February 21, 2013



Figure 1. Individual FHR measurements (n=3264 data points) by gestational age of 547 normal fetuses. Curves representing the 3rd, 50th, and 97th percentiles of FHR are shown, as is a horizontal line at 110 bpm, which is the standard obstetric definition of bradycardia. FHR decreases with advancing gestational age. Some normal FHR measurements are <3rd percentile but none are <110 bpm. FHR indicates fetal heart rate; bpm, beats per minute.

subjects #17 and #18, subjects #19 and #20, and subjects #21 and #22. Subjects #41 and #42 in Group 2 were twins. At the time of initial assessment, no Group 2 subject was known to have affected family members; however, subsequent diagnosis in the fetal proband led to a genetic diagnosis of LQTS in undiagnosed members of 6/16 (38%) families. These family members (subjects #5, #6, and #7) were included in Group 1 after diagnosis of LQTS in subjects #32, #33, and #37.

The mean GA at delivery was slightly less for Group 2 (36.4±2.8 weeks) compared with Group 1 (38.0±2.7 weeks) subjects, but this difference was not significant (P=0.08). The mean GA of referral for subjects in Group 2 was 27.6±4.5 weeks. Five subjects in Group 2 were delivered prematurely (≤ 35 weeks of gestation) because of uncontrolled arrhythmia or fetal distress; 1 fetus died in utero from uncontrolled arrhythmia and severe hydrops (Subject # 40).

Among mothers with LQTS, 13 were treated with β-adrenergic blocking agents during pregnancy: 11 throughout pregnancy and 2 during 3rd trimester only. The FHR was not different in fetuses whose mothers were treated (130.1±8.2 bpm) or untreated (127.5±13.6 bpm; P=0.6).

LQTS Mutations in Group 1 Versus Group 2

Mutation in a known LQT gene was found in most subjects (92%) who underwent genetic testing (95%): 23 with LQT1, 4 with LQT2, 6 with LQT3, 2 with LQT5, and 1 with a compound mutation. Three subjects were not tested and 3 subjects had uncharacterized mutations. Among those who had genetic testing, there were differences in genetic results in Group 1 versus Group 2 subjects (Table 1). For example, 83% of Group 1 subjects had a *KCNQ1* or *KCNE1* mutation, 4% had an *SCN5A* mutation, and no subject had an uncharacterized mutation. In contrast, 33% of Group 2 subjects had a *KCNQ1* mutation, 33% had an *SCN5A* mutation, and nearly 20% had uncharacterized mutations (n=3).

Fetal Heart Rates

Normal FHR data from 7 to 40 weeks were obtained from 3264 FHR measurements in 547 normal subjects. The 3rd, 50th, and 97th percentiles for GA are shown in Figure 1. We obtained 318 FHR measures from 42 LQTS fetuses; the mean of FHR measures was ≈8 per fetus and the range was 1 to 12 per fetus. The mean FHR at each of the 3 GA groups (<21 weeks, 21–30 weeks, and 31–40 weeks) was significantly different between normal and LQTS subjects (P<0.001; Table 2). The FHR at the 3rd percentile of normal from the 3 GA groups were all greater than the standard obstetric definition of fetal bradycardia (ie, FHR ≤110 bpm).

We evaluated the individual FHR measures across GA of fetuses based on indication for referral. Figure 2A shows the FHR/GA profile of subjects referred for a family history; Figure 2B shows the FHR/GA profile of subjects referred for evaluation of fetal rhythm. The FHR of the LQTS fetuses decreased with GA as seen in the normal

Table 2. Mean FHR of Normal and LQTS Subjects by GA Group

GA Group	Normal Subjects FHR Mean±SE (bpm)	LQTS Subjects FHR Mean±SE (bpm)	P
<21 wk	152.0±0.4	139.9±1.2	<0.001
21 to 30 wk	146.7±0.2	127.4±1.2	<0.001
31 to 40 wk	143.3±0.4	123.0±1.4	<0.001

LQTS indicates long QT syndrome; GA, gestational age; FHR, fetal heart rate; SE, standard error; and bpm, beats per minute.

Downloaded from http://circ.ahajournals.org/ at University of Tsukuba on February 21, 2013



Figure 2. Individual measurements throughout gestation of LQTS fetuses, based on indication for referral. **A**, FHR of individuals referred because of a family history of LQTS (Group 1). **B**, FHR of individuals referred for evaluation of fetal rhythm (Group 2). For reference, the line marking a FHR of 110 bpm across gestation is shown in both panels. FHR indicates fetal heart rate; LQTS, long QT syndrome; and bpm, beats per minute.

fetal cohort, but GA-dependent changes in mean FHR differed between Groups 1 and 2. Early, at <21 weeks of gestation, mean FHRs were not different (141.54±2.02 versus 136.95±2.51; P=0.15). However, FHR in Group 2 was lower at both 21 to 30 weeks (130.28±2.66 versus 124.54±2.65; P=0.04) and at 31 to 40 weeks (127.72±2.81 versus 117.94±2.83; P<0.01). Only subjects in Group 2 had FHR ≤110 bpm.

The Bradycardia Index

Among LQTS subjects, only 15% of FHR readings were ≤110 bpm whereas 66% of the FHR readings were ≤3rd percentile for GA. Thus, 85% of the total FHR readings were higher than the standard obstetric definition of bradycardia (FHR ≤110 bpm), and only 33% of the LQTS FHR readings were >3rd percentile for GA. Using FHR ≤3rd percentile for GA, 38% (16/42) of LQTS fetuses had a bradycardia index of 100% and 67% (28/42) had a bradycardia index between 75% to 100%. Table 3 shows there were significant differences between Groups 1 and 2 in the bradycardia indices for FHR ≤110 bpm and ≤3rd percentile for GA. Within Group 2, a bradycardia index of 100% was seen in 2/3 subjects with complex rhythms (Table 4). The findings of more pronounced bradycardia in Group 2 subjects with complex rhythms may be another manifestation of a more severe phenotype in such fetal LQTS subjects.

Table 3. Bradycardia Index of Group 1 and Group 2 Based on GA Group

	FHR≤110 bpm		FHR<3rd Percentile for GA	
GA (Weeks)	Group 1	Group 2	Group 1	Group 2
Overall	1%	31%	50%	68%
<21	0%	6%	48%	45%
21 to 30	2%	26%	61%	68%
31 to 40	2%	49%	42%	81%

LQTS indicates long QT syndrome; GA, gestational age; FHR, fetal heart rate; and bpm, beats per minutes.

Although the sample sizes of certain LQTS mutations were small, among genotypes, the bradycardia index for FHR ≤3rd percentile for GA was highest (100%) for uncharacterized mutations and lowest (0%) for LQT5 mutations. Overall, the severity of the bradycardia index was not predicted by the presence of mutations in known LQTS genes.

Fetal Heart Rhythms and FHR

In most of the 42 fetuses, sinus rhythm was observed throughout pregnancy, but in 10 fetuses, 8 of whom were in Group 2, complex arrhythmias characterized by 2° AV block or TdP were observed (Table 4). The mean FHRs of these 10 subjects were lower across GA than those subjects who manifested only fetal bradycardia (120.74±3.56 versus 130.79±2.37; P<0.01), and the bradycardia indices for FHR ≤3rd percentile were higher (80% versus 60%).

Discussion

There are several novel and clinically relevant findings in this study of fetal LQTS. First, as in normal fetuses, the FHR of LQTS subjects trend downward but are generally lower than FHR of normal fetuses as gestation progresses. Second, there are GA-dependent FHR predictors of LQTS; for example, when compared with a GA independent FHR predictor (FHR ≤110 bpm), a FHR ≤3rd percentile for GA improves ascertainment of LQTS subjects from 15% to 85%. Third, there are shades of bradycardia within the LQTS population: compared with subjects who remained in sinus rhythm during pregnancy, subjects with the lowest FHRs were more likely to have had a complex arrhythmia including TdP or 2° AV block, and were more likely to have de novo or uncharacterized mutations. Together, findings from this study should improve ascertainment of fetal LQTS at all GA.

From the first ultrasound visualization of the fetal heart signifying a viable pregnancy to the reactive accelerations signifying fetal well-being during labor and delivery, FHR is the most frequently and thoroughly evaluated parameter

Downloaded from http://circ.ahajournals.org/ at University of Tsukuba on February 21, 2013